About Allomek

Allomek History

AlloMek Therapeutics was formed to develop, and out-license, a novel class of MEK inhibitors represented by the lead compound CIP-137401.
CIP-1374 was discovered by Cheminpharma, LLC team. All intellectual property and rights related to CIP-1374 were transferred from Cheminpharma to AlloMek Therapeutics.
AlloMek is a virtual company that relies on high quality Contract Research Organizations to execute experiments to further the development of its MEK program.